MTOR表达在HPV阳性与阴性头颈癌放化疗患者中的预后意义
本研究利用109例接受根治性放化疗的头颈鳞癌患者组织芯片,检测p16与MTOR表达并分析其与临床病理特征及预后的关联。结论认为MTOR表达的预后意义取决于HPV状态。
要点
- MTOR表达与HPV状态及临床病理特征无关。
- HPV阴性患者中MTOR高表达预示更差局部区域控制、无病生存和总生存。
- HPV阳性患者中MTOR表达与预后无关。
核心结论
- MTOR表达的预后意义取决于HPV状态,仅在HPV阴性头颈鳞癌放化疗患者中预测不良结局。
研究设计与样本
- 回顾性组织芯片研究,纳入109例接受根治性放化疗的头颈鳞癌患者,检测p16与MTOR表达并关联临床病理特征及结局。
主要发现
- MTOR在肿瘤核心间变异大,与HPV状态或临床病理特征无关。
- HPV阳性患者中,MTOR表达与结局无关。
临床怎么用
- 在HPV阴性头颈鳞癌放化疗患者中,MTOR表达可能作为预后分层标志物。
- HPV阳性患者中MTOR表达不推荐用于预后判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The mechanistic target of rapamycin (MTOR) plays a key role in regulating cell growth and metabolism and is commonly overexpressed in head and neck cancer (HNSCC). This study investigated the association of MTOR with clinical outcome in human papilloma virus (HPV) positive and negative HNSCC patients treated by chemoradiation. METHODS: A tissue microarray (TMA) consisting of cores from 109 HNSCC patients treated by definitive chemoradiation was constructed and stained with antibodies against p16 and MTOR and expression correlated with clinicopathological features and clinical outcome. RESULTS: MTOR varied widely between tumor cores and was not associated with HPV status or clinicopathological features. There was a positive correlation with pre-treatment FDG uptake. (P = .01). In HPV negative patients, MTOR predicted for shorter locoregional control (P = .02), diseases free survival (P = .02), and overall survival (P = .04). MTOR expression was not associated with outcome in HPV positive patients. CONCLUSIONS: Prognostic significance of MTOR expression depends on HPV status.
引用
- Wilson TG, Hanna A, Recknagel J, et al. Prognostic significance of MTOR expression in HPV positive and negative head and neck cancers treated by chemoradiation. Head Neck. 2019. PMID: 31657099. doi:10.1002/hed.25983
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。